Glucoregulation after canine islet transplantation: Contribution of insulin secretory capacity, insulin action, and the entero-insular axis

Cell Transplantation

Volumn 6, Issue 5, 1997, Pages 497-503

  Van Der Burg, Michael P M ^a   Van Suylichem, Paul T R ^b   Guicherit, Onno R ^a   Frölich, Marijke ^a   Lemkes, Herman H P J ^a   Gooszen, Hein G ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Islet of Langerhans; Transplantation

Indexed keywords

ARGININE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOTRANSPLANTATION; CONTROLLED STUDY; DOG; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET TRANSPLANTATION; POSTPRANDIAL STATE; PRIORITY JOURNAL; SPLEEN;

ANIMALS; BLOOD GLUCOSE; DOGS; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; PEPTIDES; POSTPRANDIAL PERIOD;

ANIMALIA; CANIS FAMILIARIS; SUIDAE;

EID: 0030769805     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0963-6897(97)00050-X     Document Type: Article

References (29)

1. Ahrén, B.; Larsson, H.; Holst, J.J. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:473-478; 1997.
2. Finegood, D.T.; Pacini, C.; Bergman, R.N. The insulin sensitivity index: Correlation in dogs between values determined from the intravenous glucose tolerance test and the euglycemic glucose clamp. Diabetes 33:362-368; 1984.
3. Gutniak, M.; Ørskov, C.; Holst, J.J.; Ahren, B.; Efendic, S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326:1316-1322; 1992.
4. Hering, B.J.; Browatzki, C.C.; Schultz, A.; Bretzel, R.G.; Federlin, K.F. Clinical islet transplantation - registry report, accomplishments in the past and future research needs. Cell Transplant. 2:269-282; 1993.
5. Kawai, K.; Suzuki, S.; Ohashi, S.; Mukai, H.; Murayma, Y.; Yamashita, K. Effects of truncated glucagon-like peptide-1 on pancreatic hormone release in normal conscious dogs. Acta Endocrinol. 123:661-667; 1990.
6. Krarup, T. Immunoreactive gastric inhibitory polypeptide. Endocr. Rev. 9:122-134; 1988.
7. Leahy, J.L.; Cooper, H.E.; Weir, G.C. Impaired insulin secretion associated with near normoglycemia. Diabetes 36:459-464; 1987.
8. Luzi, L.; Hering, B.J.; Socci, C.; Raptis, G.; Battezzati, A.; Terruzzi, I.; Falqui, L.; Brandhorst, H.; Brandhorst, D.; Regalia, E.; Brambilla, E.; Secchi, A.; Perseghin, G.; Maffi, P.; Bianchi, E.; Mazzaferro, V.; Gennari, L.; Di Carlo, V.; Federlin, K.; Pozza, G.; Bretzel, R.G. Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus. J. Clin. Invest. 97: 2611-2618; 1996.
9. Nauck, M.A.; Heimesaat, M.M.; Ørskov, C.; Holst, J.J.; Ebert, R.; Creutzfeldt, W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91:301-307; 1993.
10. Nauck, M.A.; Siegel, E.G.; Creutzfeldt, W. Prolonged maximal secretion of insulin secretion in healthy subjects does not provoke preferential release of proinsulin. Pancreas 6:645-652; 1991.
11. Ørskov, C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35:701-711; 1992.
12. Ørskov, C.; Wettergren, A.; Holst, J.J. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661; 1993.
13. Ørskov, L.; Holst, J.J.; Møller, J.; Ørskov, C.; Møller, N.; Alberti, K.G.M.M.; Schmitz, O. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39:1227-1232; 1996.
14. Pyzdrovvski, K.L.; Kendall, D.M.; Halter, J.B.; Nakhleh, R.E.; Sutherland, D.E.; Robertson, R.P. Preserved insulin secretion and insulin independence in recipients of islet autografts. N. Engl. J. Med. 327:220-226; 1992.
15. Rossetti, L.; Shulman, G.I.; Zawalich, W.; DeFronzo, R.A. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomised rats. J. Clin. Invest. 80:1037-1044; 1987.
16. Rossetti, L.; Smith, D.; Shulman, G.I.; Papachristou, D.; DeFronzo, R.A. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J. Clin. Invest. 79:1510-1515; 1987.
17. Scharp, D.W.; Marchetti, P.; Swanson, C.; Newton, M.; McCullough, C.S.; Olack, B. The effect of transplantation site and islet mass on long-term survival and metabolic and hormonal function of canine purified islet autografts. Cell Transplant. 1:245-254; 1992.
18. Strack, T.R.; Greenberg, G.R.; Polonsky, K.S.; Albisser, A.M. The effect of a time delay on the characteristics of the canine glucoregulatory system. Metabolism 39:1219-1224; 1990.
19. Strubbe, J.H.; Steffens, A.B. Neural control of insulin secretion. Horm. Metab. Res. 25:507-512; 1993.
20. Tobin, B.W.; Lewis, J.T.; Tobin, B.L.; Rajotte, R.V.; Finegood, D.T. Markedly reduced β-cell function does not result in insulin resistance in islet autografted dogs. Diabetes 41:1172-1181; 1992.
21. Van der Burg, M.P.M.; Gooszen, H.G. The metabolic efficiency of islet grafts: An overview. In: Hesse, U.J.; Pichlmaier, H., eds. Islet transplantation - current status of clinical application and experimental results. Lengerich, Germany: Wolfgang Pabst Verlag; 1992:93-99.
22. Van der Burg, M.P.M.; Guicherit, O.R.; Frölich, M.; Scherft, J.P.; Prins, F.A.; Bruijn, J.A.; Gooszen, H.G. Assessment of islet isolation efficacy in dogs. Cell Transplant. 3:91-101; 1994.
23. Van der Burg, M.P.M.; Guicherit, O.R.; Frölich, M.; Gooszen, H.G. Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon-like peptide-1 during perifusion of short-term cultured canine isolated islets. Regul. Pept. 60:61-67; 1995.
24. Van der Burg, M.P.M.; Guicherit, O.R.; Jansen, J.B.M.J.; Frölich, M.; Lamers, C.B.H.W.; Lemkes, H.H.P.J.; Bruijn, J.A.; Gooszen, H.G. Function and survival of intrasplenic islet autografts in dogs. Diabetologia 39:37-44; 1996.
25. Van Suylichem, P.T.R.; Strubbe, J.H.; Houwing, H.; Wolters, G.H.J.; Van Schilfgaarde, R. Insulin secretion by rat islet isografts of a defined endocrine volume after transplantation to three different sites. Diabetologia 35: 917-923; 1992.
26. Ward, W.K.; Bolgiano, D.C.; McKnight, B.; Halter, J.B.; Porte, D. Diminished B cell secretory capacity in patients , with noninsulin-dependent diabetes mellitus. J. Clin. Invest. 74:1318-1328; 1984.
27. Ward, W.K.; Wallum, B.J.; Beard, J.C.; Taborsky, J.; Porte, D. Reduction of glycemic potentiation: sensitive indicator of β-cell loss in partially pancreatectomized dogs. Diabetes 37:723-729; 1988.
28. Warnock, G.L.; Ao, Z.; Cattral, M.S.; Dabbs, K.D.; Rajotte, R.V. Experimental islet transplantation in large animals. In: Ricordi, C., ed. Pancreatic islet cell transplantation. Austin: R.G. Landes Company; 1992:261-278.
29. Yki-Järvinen, H.; Koivisto, V.A. Natural course of insulin resistance in type I diabetes. N. Engl. J. Med. 315:224-230; 1986.